3315F Er+ or pr+ breast cancer
Also known as: ER positive breast cancer, PR positive status, hormone receptor positive
Performance measure documenting estrogen receptor positive or progesterone receptor positive breast cancer. Quality metric for hormone receptor status determination.
In Plain Language
breast cancer that responds to hormone therapy
Clinical Context
Quality measure documenting hormone receptor status essential for predicting response to endocrine therapy and guiding treatment selection in breast cancer.
RVU Information
CPT 3315F does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Documentation should include the clinical indication, service details, and any applicable performance metrics. Coverage may vary by payer — verify acceptance before billing.
Specialties
Frequently Asked Questions
What is CPT code 3315F?
CPT 3315F (Er+ or pr+ breast cancer) is a Other code. Performance measure documenting estrogen receptor positive or progesterone receptor positive breast cancer. Quality metric for hormone receptor status determination.
Who uses CPT code 3315F?
CPT 3315F is used by Oncology, Breast Surgery, Quality Reporting. Quality measure documenting hormone receptor status essential for predicting response to endocrine therapy and guiding treatment selection in breast cancer.
When is CPT 3315F used?
Quality measure documenting hormone receptor status essential for predicting response to endocrine therapy and guiding treatment selection in breast cancer.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.